Detrimental effects of prolonged inadequate nutrition

A reduced or absent appetite is a commonly encountered problem in feline medicine. Even healthy cats have the potential to be picky eaters. A cat that is unwell may present with inappetence or anorexia as one of the first clinical signs. Cats have a higher protein and amino acid requirement than most other species and become protein malnourished quickly when anorexic. Cats are dependent on protein for gluconeogenesis and are unable to downregulate production of aminotransferases and urea cycle enzymes in response to low protein intake. Prolonged inadequate nutrition should be avoided as this may be more detrimental to the patient than the primary underlying disorder. Compromised immunity, delayed wound healing and altered hepatic metabolism are all possible sequelae.

Cats are predisposed to accumulating triglycerides within hepatocytes and most systemically unwell cats develop some degree of hepatocellular fatty vacuolation. Lipidosis occurs during periods of inadequate nutrition regardless of cause (e.g., systemic illness, behavioural or environmental factors), with overconditioned individuals most at risk. This emphasises the importance of resuming and maintaining adequate food intake in cats that have been anorexic for longer than 3 days. While the ultimate goal for the clinician is to diagnose and treat underlying condition(s), symptomatic therapy during the diagnostic phase may be equally important to ensure a satisfactory outcome for the patient.
Appetite regulation

Ingestion of food is influenced by a complex system of interrelated metabolic, gastrointestinal and sensory signals. Taste, odour and texture of foods can all affect a patient’s motivation to eat, and dietary preferences are often dependent on previous feeding experiences. Mastication, distension of the gastrointestinal tract and postabsorptive changes in nutrient levels in the blood stimulate the release of hormones which impact the control of further food intake. For example, mastication results in dopamine release, which has a stimulatory effect on food intake, while most amino acids stimulate release of cholecystokinin, which inhibits appetite. A number of other neurotransmitters such as catecholamines, serotonin and gamma-aminobutyric acid (GABA) also have a physiological role in the control of food intake, as described schematically in the box below.

Noxious internal (nociception, nausea or ileus) or external (environmental) stimuli may override all other inputs. All stimuli that influence feeding are integrated in the brain by hormonal and neuronal pathways. Important sites within the brain for control of hunger and satiety include the hypothalamus, especially the lateral and ventromedial nuclei, and the parabranchial nucleus in the caudal brainstem. While the complexity of appetite regulation makes control of all components a challenge, it also offers multiple opportunities to manipulate appetite through management of external environmental and palatability factors, as well as pharmacological support of hunger cues.

Food aversion may be an important factor in feline inappetence, and can be associated with any food that is offered when a cat is feeling nauseous, vomiting, painful or indisposed. This aversion may persist even after recovery and highlights the importance of addressing these issues, not only to help improve appetite and hydration status, but also to help prevent continued rejection of certain foods after the patient returns home.

Management of all factors contributing to inappetence is important – not only to address nutritional and hydration status, but also to help limit the development of food aversions.
Role of appetite stimulation

Appetite stimulation can play a valuable role in the management of anorectic and inappetent patients by inducing voluntary eating, thus improving their nutritional status and ability to recover from illness or injury. It is important to be aware of the limitations and appropriate role of pharmacological appetite stimulants in clinical practice. Appetite stimulants should not be used as a substitute for accurate diagnosis and specific treatment of disease. It is important to ensure provision of adequate analgesia and address ileus, nausea and pyrexia before administering these medications. Appetite stimulants are not considered to be effective in very ill patients (Figure 1), but can be useful in a number of situations (see below).

When to consider appetite stimulants

- For short-term treatment during the diagnostic phase
- For persistent moderate inappetence without any physical impediment to prehension or ingestion
- When behavioural or environmental causes of anorexia are suspected and dietary manipulation has been unsuccessful
- When trying to overcome food aversions once the underlying cause of the anorexia is resolved
- To support nutritional intake in chronically ill cats (eg, those with chronic kidney disease) or cancer cases receiving palliative treatment (Figure 2)

It is important to be aware that witnessing food ingestion does not necessarily indicate adequate caloric intake. Accurate measurement of food consumed and a comparison with the calculated resting energy requirements (RER) of the patient (eg, [30 x body weight (kg)] + 70) should be performed and used as a minimum baseline. The patient should be weighed daily using scales accurate for cats. Continued weight loss indicates an increased caloric requirement. If caloric intake remains insufficient after 2–3 days of using an appetite stimulant (or maximum 3–5 days since cessation of food intake), further measures, including enteral feeding, must be considered.

Cats have a higher requirement for some B vitamins when compared with dogs. Experimental depletion of B vitamins results in anorexia in other species. Supplementation with B vitamins may prevent this occurring, although no evidence exists to confirm this. Still, provision of B vitamins is simple and should be considered in all inappetent cats.

Pharmacological options

A variety of agents have been used in cats for pharmacological appetite stimulation, and these are discussed in turn below, with dosage information provided in Table 1. Note, however, that only cyproheptadine and mirtazapine can currently be recommended for this purpose.

Anabolic steroids

Nandrolone decanoate (Deca-Durabolin, Organon; Laurabolin, MSD Animal Health) and stanozolol (Winstrol; Winthrop-Breon) have historically been used as appetite stimulants. The positive nitrogen balance associated with the use of anabolic steroids in debilitated animals has been shown to be the mechanism of appetite-stimulating action. The effects of anabolic steroids can be longer lived, but are less pronounced and less predictable, than those of glucocorticoids or benzodiazepines.
Use of appetite stimulants in cats

Anabolic steroids are no longer recommended for appetite stimulation.

**Benzodiazepines**

Benzodiazepines are thought to cause direct appetite stimulation within the central nervous system. They enhance inhibitory neurotransmission mediated by GABA, with receptors located on GABA<sub>a</sub> receptor proteins. The hyperphagia induced is likely mediated by the α2/α3 subtype, with the probable site of action being the parabranchial nucleus in the caudal brainstem.

Diazepam (Valium; Roche) has traditionally been the most frequently used benzodiazepine appetite stimulant, and is more effective when given intravenously than orally.

**Table 1 Appetite stimulants used in cats**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Class/mechanism of action</th>
<th>Dosage</th>
<th>Renal insufficiency dosing changes</th>
<th>Hepatic disease dosing changes</th>
<th>Other notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyproheptadine</td>
<td>Serotonin antagonist antihistamine</td>
<td>0.25–0.5 mg/kg q24–72h once</td>
<td>Caution if renal disease</td>
<td>Contraindicated in presence of hepatic dysfunction</td>
<td>Avoid oral dosing due to risk of acute hepatic necrosis</td>
</tr>
<tr>
<td>Nandrolone</td>
<td>Anabolic steroid</td>
<td>1 mg/cat PO q12–24h</td>
<td>No published reference dose alterations</td>
<td>Contraindicated in nephrotic stage of nephritis</td>
<td>Used for palliation only. Not for prolonged use.</td>
</tr>
<tr>
<td>Oxazepam*</td>
<td>Benzodiazepine</td>
<td>1 mg/cat PO q12–24h</td>
<td>1 mg/cat PO q12h</td>
<td>Reducing dose by up to 30%</td>
<td>Mirtazapine has been associated with blood dyscrasias in humans, and subclinical ALT elevations in both feline and human patients. Do not use with cyproheptadine for appetite stimulation</td>
</tr>
<tr>
<td>Prednisolone*</td>
<td>Glucocorticoid</td>
<td>1 mg/cat PO q12–24h</td>
<td>Caution if renal disease</td>
<td>Use with caution in presence of hepatic dysfunction</td>
<td>Anecdotally associated with fulminant hepatic failure</td>
</tr>
<tr>
<td>Megestrol acetate*</td>
<td>Synthetic progestin</td>
<td>1 mg/cat PO q12–24h</td>
<td>No published reference dose alterations</td>
<td>Hepatic impairment may reduce clearance by up to 30%</td>
<td>Used for palliation only.</td>
</tr>
</tbody>
</table>

*Historically used appetite stimulant, no longer recommended.

IM = intramuscular; IV = intravenous; PO = oral; ALT = alanine aminotransferase

Although several options exist for pharmacological appetite stimulation, only cyproheptadine and mirtazapine can currently be recommended.

Anabolic steroids are associated with common and serious adverse effects such as sodium, calcium, potassium, water, chloride and phosphate retention, hepatotoxicity and androgenic behavioural changes. Stanozolol, in particular, has been associated with a high incidence of hepatotoxicity in cats. Anabolic steroids are contraindicated in patients with hepatic dysfunction, hypercalcaemia, cardiovascular disease, pituitary insufficiency, prostate or mammary carcinomas, benign prostatic hypertrophy and during the nephrotic stage of nephritis.
making it a more appropriate choice for use in hospital than in the home environment.\textsuperscript{17} It is important to remember, however, that appetite stimulation is rarely effective in critically ill cats. Oxazepam, available only in an oral form, may be a more powerful appetite stimulant than diazepam; however, oral administration tends to make it less effective clinically.\textsuperscript{4} Feeding usually commences within 20 mins of administration, but is short-lived, and may not result in adequate daily intake.\textsuperscript{15} Other drawbacks to the use of benzodiazepines include ataxia, sedation and unpredictable response to standard doses.\textsuperscript{4,13} These medications are metabolised in the liver, with the active metabolites eventually undergoing glucuronidation, and then excretion in the urine.

The use of oral benzodiazepines is controversial in cats due to multiple reports of serious, and almost invariably fatal, idiosyncratic hepatotoxicity observed 5–13 days after the use of oral diazepam.\textsuperscript{2,21–25} These drugs are reportedly either contraindicated, or only to be used with caution at reduced rates, in patients with hepatic dysfunction.\textsuperscript{1,21,26} Caution is also required in patients with renal disease.\textsuperscript{21} As viable, effective alternatives exist, the use of these drugs has largely been superseded.

**Cyproheptadine**
Cyproheptadine (Periactin; Merck, Figure 3) is a serotonin antagonist antihistamine which is thought to stimulate appetite through antagonism of 5-HT\textsubscript{2} receptors in the ventromedial hypothalamus. As it is nearly completely metabolised in the liver and undergoes renal excretion, dose adjustments should be made for either renal or hepatic disease.

Figure 3 Cyproheptadine is a serotonin antagonist antihistamine which is thought to stimulate appetite through antagonism of 5-HT\textsubscript{2} receptors in the ventromedial hypothalamus.

*Figure 3 Cyproheptadine is a serotonin antagonist antihistamine which is thought to stimulate appetite through antagonism of 5-HT\textsubscript{2} receptors in the ventromedial hypothalamus. As it is nearly completely metabolised in the liver and undergoes renal excretion, dose adjustments should be made for either renal or hepatic disease.*

**Glucocorticoids**
Glucocorticoids have been used for nonspecific appetite stimulation in veterinary patients for many years.\textsuperscript{1,10,31,32} The mechanism of action for appetite stimulation is unknown, but cortisol is thought to have a permissive action for other appetite-stimulating compounds such as opioids and epinephrine, and the ability of corticosteroids to stimulate metabolism has also been suggested to play a role.\textsuperscript{3,33} Corticosteroids have been demonstrated in clinical trials with human oncology patients to be effective in alleviating appetite loss, although the effect is noted to be short-lived (usually only a few weeks at best) and with a side effects profile that makes them a poor choice for prolonged use.\textsuperscript{34} Caution should also be used in cats with diabetes mellitus (due to hyperglycaemic effects) or cardiovascular disease (due to hypertensive effects caused by vasoconstriction and increased blood volume).\textsuperscript{21}

Corticosteroids should generally only be used if other effects of these medications (eg, anti-inflammatory, immunosuppressive or antineoplastic) are desired.

**Megestrol acetate**
Megestrol acetate (Ovaban, Schering-Plough; Ovariad, Virbac) is a synthetic progestin. Although less consistently observed than with other agents, it does have appetite-stimulating properties, the mechanism of action of which is poorly defined.\textsuperscript{3} Megestrol acetate is associated with serious and relatively common adverse effects including adrenocortical suppression, diabetes mellitus, increased risk of mammary adenocarcinomas, and hepatotoxicity.\textsuperscript{21,35} Making it a difficult choice to justify for all but short-term palliative cases. Contraindications include pregnancy, uterine disease, diabetes mellitus and mammary neoplasia.\textsuperscript{21} Megestrol acetate should be avoided in intact females or cats already receiving glucocorticoids.

Due to the widespread availability of agents with a higher efficacy and lower risk of side effects, it is difficult to justify the use of megestrol acetate.

**Mirtazapine**
Mirtazapine (Avanza; MSD, Figure 4) is a serotonin receptor antagonist that also antagonises pre-synaptic α\textsubscript{2}-receptors. The net increase in norepinephrine that results likely contributes most to its appetite-stimulating effects as norepinephrine acts...
at other α-receptors to increase appetite. Mirtazapine also antagonises 5-HT2 receptors, which can result in appetite stimulation via nuclei within the hypothalamus. Although mainly used as an antidepressant in humans, it has the added benefit of anti-nausea and antiemetic properties mediated primarily through antagonism of the 5-HT3 receptor.

Administration of mirtazapine in cats was first reported in 2006; however, pharmacological studies were not performed. Two subsequent, related studies have demonstrated a significant increase in food consumed after administration of mirtazapine to healthy young cats, with minimal side effects observed when a low dose was used (1.88 mg/cat). These studies identified a 9 h half-
life of mirtazapine in cats at this dose, suggesting daily dosing in healthy cats that only show a response for 24 h may be most appropriate, with no accumulation detected after 6 days of administration.

Cats with chronic kidney disease have been shown to exhibit reduced mirtazapine clearance, necessitating an extended (q48h) dosing regimen in these patients. A placebo-controlled crossover clinical trial demonstrated a statistically significant increase in appetite and weight gain in cats with stable chronic kidney disease given mirtazapine q48h over a 3 week period. Although the studies from Quimby et al found the increase in appetite to occur within 8 h of administration, authors have reported that it may take up to 36 h for a response to be seen. Adverse effects may include muscle twitching, hyperactivity, vocalisation and behavioural changes (eg, increased affection). These effects are less likely to be observed at lower doses. A subclinical elevation in alanine aminotransferase has been reported in feline and human patients, which resolved upon discontinuation of mirtazapine.

Metabolism of mirtazapine occurs via multiple pathways, including glucuronidation, and the human literature documents elimination via urine (75%) and faeces (25%). Renal impairment may reduce elimination by 30–50%, and hepatic impairment may reduce clearance by up to 30%, indicating the need to adjust dosing accordingly. Caution should be used in patients with renal or hepatic insufficiency, and in patients with diabetes mellitus due to indirect effects on blood glucose regulation. Although extremely rare, mirtazapine has also been associated with blood dyscrasias in humans.

Mirtazapine should not be used in patients receiving monoamine oxidase inhibitors (eg, selegiline) or tramadol due to an increased risk of serotonin syndrome. Serotonin syndrome is characterised by three types of neuro-excitatory symptoms including: a) neuromuscular hyperactivity (tremor, clonus, hyperreflexia, pyramidal rigidity); b) autonomic hyperactivity (pyrexia, tachycardia, tachypnoea); and c) altered mental status (agitation, excitement). In the event of serotonin syndrome occurring, cyproheptadine (a non-selective serotonin antagonist) has been suggested as an antidote. Therefore, it is not recommended that cyproheptadine and mirtazapine be administered together for appetite stimulation, as their effects may be negated by each other. As feline patients require smaller doses than the available human preparation, utilising a compounding pharmacy for accurate dosing may make the use of mirtazapine easier for clients.

The clinical approach to mirtazapine use as an appetite stimulant is described on page 754.

**Key Points**

- The complexity of appetite regulation makes control of all components a challenge, but also offers multiple opportunities to manipulate appetite through management of external environmental and palatability factors, as well as pharmacological support of hunger cues.
- While not indicated for every inappetent cat, appetite stimulants do have a role in supporting nutrition for a select group of feline patients.
- A careful history, physical examination and knowledge or suspicion of underlying disease states can help direct the selection and use of these medications.

**Funding**

The authors received no specific grant from any funding agency in the public, commercial or not-for-profit sectors for the preparation of this article.

**Conflict of interest**

The authors declare that there is no conflict of interest.

**References**

13. Sparkes AH. Assessing and tempting the ‘finicky’ cat. Proceedings of the
Use of appetite stimulants in cats


